Apellis Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Apellis Pharmaceuticals hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	1.9%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$2.73
Prognose der Dividendenrendite	0%

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Sep 27

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Aug 09

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Jul 12

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

May 30

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

May 30

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

May 14

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 09

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Feb 16

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

Jul 19

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

May 13

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Apr 18

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt Sensibly?

Dec 14

Some Analysts Just Cut Their Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Estimates

Nov 09

Apellis Pharmaceuticals: Trying To Develop A Blockbuster Franchise

Sep 28

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von APLS in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von APLS gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Apellis Pharmaceuticals Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von APLS im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (APLS)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Biotechs)	1.9%
Analystenprognose (APLS) (bis zu 3 Jahre)	0%

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von APLS im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von APLS im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von APLS, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da APLS keine Ausschüttungen gemeldet hat.

Apellis Pharmaceuticals Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Investors Aren't Buying Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) Revenues

Apellis: Rare Kidney Disease Data Leads To Possible First To Market

Sobi and Apellis Announce Positive Topline Results from Phase 3 Valiant Study of Pegcetacoplan in C3G and Primary IC-MPGN

Price target decreased by 7.6% to US$69.12

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 11%

Health Check: How Prudently Does Apellis Pharmaceuticals (NASDAQ:APLS) Use Debt?

Independent Director notifies of intention to sell stock

What Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) P/S Is Not Telling You

It's Probably Less Likely That Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) CEO Will See A Huge Pay Rise This Year

Apellis Pharmaceuticals, Inc. Announces Positive One-Year Data from Phase 2 Study of Pegcetacoplan in Post-Transplant Recurrence of C3G and IC-MPGN Presented as Late-Breaker at ERA Congress

Consensus EPS estimates fall by 17%

Apellis Pharmaceuticals Strives For Recovery Despite Syfovre Setbacks

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 18%

Apellis Pharmaceuticals, Inc., Annual General Meeting, Jun 05, 2024

Apellis Announces Pegcetacoplan MAA Review Reset to Initial Assessment by European Medicines Agency

Consensus EPS estimates upgraded to US$0.98 loss

Consensus EPS estimates upgraded to US$1.00 loss

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Chief Technical Operations Officer recently sold US$646k worth of stock

Apellis Pharmaceuticals, Inc. Announces Appointment of Philip Ferrone, M.D as Chief Medical Retina Advisor, Effective March 18, 2024

Consensus EPS estimates fall by 13%, revenue upgraded

Co-Founder notifies of intention to sell stock

New minor risk - Financial position

Apellis Pharmaceuticals: Eye Disease Drug Syfovre On Comeback Trail - But Risks Remain

Apellis Pharmaceuticals, Inc. Announces Negative CHMP Opinion for Pegcetacoplan for Ga in the European Union and Plans to Seek Re-Examination of Application

Co-Founder notifies of intention to sell stock

Apellis Pharmaceuticals, Inc. Appoints Adam Townsend as Chief Operating Officer

Co-Founder recently sold US$525k worth of stock

Price target increased by 9.0% to US$71.44

Price target decreased by 9.6% to US$66.69

Apellis Pharmaceuticals, Inc. Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union

Apellis Pharmaceuticals, Inc. and Sobi Presents Post Hoc Data that Reinforce the Long-Term Efficacy and Safety of EMPAVELI

CFO & Treasurer exercised options and sold US$633k worth of stock

Insufficient new directors

Apellis Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $300 million.

Sobi and Apellis Pharmaceuticals, Inc. Announce Positive Results from Phase 2 NOBLE Results of Pegcetacoplan in Post-Transplant Recurrence of Primary IC-MPGN and C3G

Apellis Pharmaceuticals, Inc. Announces U.S. FDA Approval of the EMPAVELI® Injector, a Device to Streamline Self-Administration

Apellis Pharmaceuticals, Inc. Receives Permanent J-Code (J2781) for SYFOVRE® (Pegcetacoplan Injection), Effective October 1, 2023

Levi & Korsinsky, LLP Notifies Investors in Apellis Pharmaceuticals, Inc. of Class Action Securities Lawsuit

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Announces Corporate Restructuring to Drive Growth of SYFOVRE and EMPAVELI

Apellis Pharmaceuticals, Inc. Provides Updates on Injection Kits and Rare Safety Events with SYFOVRE (Pegcetacoplan Injection)

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Kessler Topaz Meltzer & Check, LLP and Bernstein Litowitz Berger & Grossmann LLP Files Securities Class Action Lawsuit Against Apellis Pharmaceuticals, Inc

No longer forecast to breakeven

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Apellis Pharmaceuticals, Inc. Provides Update on Review of Rare Safety Events with SYFOVRE® for Geographic Atrophy

Price target decreased by 9.8% to US$93.23

With A 55% Price Drop For Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) You'll Still Get What You Pay For

New minor risk - Share price stability

General Counsel notifies of intention to sell stock

Chief People Officer notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Analysts Are Betting On Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) With A Big Upgrade This Week

Consensus revenue estimates increase by 57%, EPS downgraded

Price target increased by 12% to US$100

Chief Commercial Officer notifies of intention to sell stock

Insufficient new directors

Is Apellis Pharmaceuticals (NASDAQ:APLS) Using Debt In A Risky Way?

Chief Commercial Officer notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock

Co-Founder exercised options to buy US$6.5m worth of stock.

Co-Founder & Director exercised options and sold US$62k worth of stock

Price target increased by 13% to US$85.06

FDA Approves Syfovre (Pegcetacoplan Injection) as the First and Only Treatment for Geographic Atrophy (GA)

Co-Founder notifies of intention to sell stock

Co-Founder & Director notifies of intention to sell stock

Chief Commercial Officer notifies of intention to sell stock